Foghorn Therapeutics
500 Technology Square
Suite 700
Cambridge
Massachusetts
02142
United States
Website: https://foghorntx.com/
Email: info@foghorntx.com
62 articles with Foghorn Therapeutics
-
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
3/9/2023
Foghorn® Therapeutics Inc. today provided a corporate update including the Company’s 2023 strategic priorities and 2022 key achievements in conjunction with its 10-K filing for the year ending December 31, 2022.
-
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
3/1/2023
Foghorn ® Therapeutics Inc. today announced that it will participate at Cowen’s 43rd Annual Health Care Conference, which is taking place March 6–8, 2023, at the Boston Marriott Copley Place in Boston, MA.
-
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
1/9/2023
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced its strategic objectives for 2023.
-
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
12/5/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical data for its FHD-286 program will be presented in a poster at the 64th Annual American Society of Hematology (ASH) Meeting.
-
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
11/22/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief Executive Officer, will participate in the Evercore ISI HealthCONx Conference which will be held virtually on November 30, 2022.
-
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
11/14/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the Company will share preclinical data for FHD-609, a first-in-class, highly potent and selective degrader of BRD9, at the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting.
-
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
11/9/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for its FHD-286 program will be highlighted in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
-
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
11/8/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended September 30, 2022.
-
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
10/27/2022
Foghorn® Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, announced the election of Thomas Lynch Jr., M.D., to its Board of Directors.
-
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
10/26/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today will present new data across its protein degradation platform at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit.
-
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
10/20/2022
Foghorn ® Therapeutics Inc. today announced that the Company will present new data at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit.
-
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
9/27/2022
Foghorn® Therapeutics Inc. announced that the Company will participate in the Bank of America 2022 Precision Oncology Conference, which will be held virtually on October 3rd, 2022.
-
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences in September 2022
9/1/2022
Foghorn® Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, announced management's participation in upcoming investor conferences in September.
-
Foghorn Therapeutics Announces Change to Board of Directors
8/31/2022
Foghorn® Therapeutics Inc. announced that Cigall Kadoch, Ph.D., a co-founder of the Company, has accepted her appointment as an Investigator for the Howard Hughes Medical Institute, effective on September 6, 2022.
-
Shares of Foghorn are tumbling after the FDA placed a full clinical hold on a Phase I dose escalation study that had already been subject to a partial hold following a patient death.
-
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
8/23/2022
Foghorn ® Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on the Phase 1 dose escalation study of FHD-286.
-
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences - Aug 01, 2022
8/1/2022
Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced management's participation in the following investor conferences in August.
-
Foghorn Therapeutics Announces Upcoming Investor Conference Participation
5/31/2022
Foghorn® Therapeutics Inc. announced management's participation in the following investor conferences.
-
The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.
-
Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
5/19/2022
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced the Food and Drug Administration (FDA) has placed the Phase 1 dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) on a partial clinical hold.